Physician profile
Richard Panicco
NPI 1891757621
$19,963.58
in general payments reported to CMS, 2019-2025
40 companies · $3,464 in 2025
The $3,464 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,741 · 2020: $2,194 · 2021: $2,472 · 2022: $2,996 · 2023: $3,048 · 2024: $3,049 · 2025: $3,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,495 · Gift: $40.92 · Education: $25.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,494.88 |
| Gift | $40.92 |
| Education | $25.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,923.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,507.99 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $1,711.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,682.74 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,254.53 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $829.43 | 2019-2024 | Epclusa |
| Celgene Corporation | $800.99 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $622.10 | 2019-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $496.31 | 2019-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $457.73 | 2019-2024 | Linzess |
| Ardelyx, INC. | $421.48 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $392.86 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $383.77 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $301.27 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $265.00 | 2020-2024 | Dificid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $216.22 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $207.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $183.67 | 2020-2022 | |
| Organon LLC | $172.01 | 2023-2025 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $135.12 | 2019-2022 | |
| Allergan, INC. | $134.36 | 2019 | |
| Amgen INC. | $93.14 | 2020-2023 | Avsola, Amjevita |
| E.R. Squibb & Sons, L.L.C. | $82.16 | 2021 | |
| Aimmune Therapeutics, INC. | $81.24 | 2024-2025 | Vowst, Zenpep |
| Concordia Pharmaceuticals INC. | $70.82 | 2019 | |
| Vivus LLC | $70.24 | 2021-2023 | Qsymia |
| Daiichi Sankyo INC. | $53.86 | 2019-2020 | |
| Novo Nordisk INC | $50.65 | 2024-2025 | Wegovy |
| Shionogi INC | $49.55 | 2019 | |
| Lilly USA, LLC | $48.57 | 2025 | Omvoh |
| Sandoz INC. | $45.25 | 2023-2024 | Hyrimoz |
| Alfasigma USA, INC. | $37.69 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $30.49 | 2021-2023 | |
| Boston Scientific Corporation | $28.90 | 2023-2025 | Resolution 360 Clip, Spaceoar Vue System - 10ml |
| Celltrion USA INC. | $25.19 | 2024 | Zymfentra |
| Astrazeneca Pharmaceuticals Lp | $24.15 | 2019 | |
| Ucb, INC. | $23.18 | 2019 | |
| Fresenius Kabi USA, LLC | $20.10 | 2023 | Idacio |
| Shire North American Group INC | $17.00 | 2019 | |
| Biofire Diagnostics, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Panicco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.